Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2025 Oct 27;17:2441–2457. doi: 10.2147/CMAR.S540752

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2025 Lv et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v4.0) License (http://creativecommons.org/licenses/by-nc/4.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Serum tRF5-23-GlyTCC-2 combined with CEA enhances the adjunctive diagnosis of CRC. (A) ROC curves comparing the ability of tRF5-23-GlyTCC-2 and CEA to discriminate between colorectal cancer (CRC) patients (n=122) and healthy donors (n=120). (B) ROC curves comparing the ability of tRF5-23-GlyTCC-2, CEA, and their combination to discriminate between colorectal cancer (CRC) patients (n=122) and healthy donors (n=120). (C) ROC curves comparing the ability of tRF5-23-GlyTCC-2 and CEA to discriminate between CRC patients (n=122) and patients with colon polyps (n=71). (D) ROC curves comparing the ability of tRF5-23-GlyTCC-2, CEA, and their combination to discriminate between CRC patients (n=122) and patients with colon polyps (n=71).